Neoadjuvant Immunotherapy for T4 dMMR Colon Cancer
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-75
SponsorPeking Union Medical College Hospital
About this trial
Due to dMMR colon cancer patients respond poorly to conventional chemotherapy, but immunotherapy can significantly improve the pCR in this group of patients, this study intends to explore whether neoadjuvant immunotherapy can improve the R0 resection rate with preservation of adjacent organs in T4 colon cancer patients with dMMR.
Eligibility criteria
Qualifiers
Aged 18-75 years;
ECOG score 0-2;
Adenocarcinoma confirmed by pathology and dMMR confirmed by IHC or PCR;
Tumor located in cecum, ascending colon, transverse colon and sigmoid colon;
Disqualifiers
A history of other malignant tumors (other than cured basal cell carcinoma, cervical carcinoma in situ, surgically treated localized prostate cancer, or surgically resected breast ductal carcinoma in situ) within the past 5 years;
Complicated with intestinal obstruction, intestinal perforation, gastrointestinal bleeding and other patients requiring emergency surgery; pregnant or lactating women;
Patients with a history of severe mental illness, immune disease, hormone medication;
Patients contraindicated by immunotherapy or surgery;
Trial design
Treatments tested in this trial
- Camrelizumab
Treatment groups
18 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov